Loading…
Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline
Summary Vascular problems are very common in systemic sclerosis with 95% of patients suffering with Raynaud's phenomenon at some stage in their illness.1 Acute ischaemic lesions are much less common, but when they occur are a serious complication, and are often difficult to treat. Many drugs ha...
Saved in:
| Published in: | Clinical and experimental dermatology 1989-03, Vol.14 (2), p.161-162 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633 |
| container_end_page | 162 |
| container_issue | 2 |
| container_start_page | 161 |
| container_title | Clinical and experimental dermatology |
| container_volume | 14 |
| creator | GOODFIELD, M.J.D. ROWELL, N.R. |
| description | Summary
Vascular problems are very common in systemic sclerosis with 95% of patients suffering with Raynaud's phenomenon at some stage in their illness.1 Acute ischaemic lesions are much less common, but when they occur are a serious complication, and are often difficult to treat. Many drugs have been used in this situation, including both oral and intravenous vaso‐dilators2,3 and low molecular weight dextran,4 each with varying degrees of success. The phosphodiesterase inhibitor, pentoxifylline, is reported to be useful in peripheral vascular disease,5 and in Raynaud's phenomenon,6 and the intravenous form is indicated for acute peripheral ischaemia, though its use in the context of connective tissue disease has not so far been reported. We now report the use of intravenous pentoxifylline in two patients with acute peripheral gangrene due to systemic sclerosis. |
| doi_str_mv | 10.1111/j.1365-2230.1989.tb00917.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79384201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79384201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633</originalsourceid><addsrcrecordid>eNqVUU2P0zAUtBBoKYWfgBQhxC3Fjr9iDkioLAuoWi6VQHuxHOdl18Vxip2y7b_HUaPe8cWSZ-a9mTFCbwhekXze71aECl5WFc0PqlarscFYEbk6PkGLC_QULTDFshSK1s_Ri5R2GBNKJL9CVxVXNVPVAt1tI5ixhzAWQ1fsIbr9A0Tji3sT7iMEKNoDFONQpFMaoXe2SNZDHJJLxaMbHwoXxmj-QhgOKcvDOBxdd_LeBXiJnnXGJ3g130u0_XK9XX8tNz9uvq0_bUrLqCAlt1ZAzVpssynScgqsIQ03pGst7qgRteWmtUZCTQhmIBvWWSwFBoWVoHSJ3p3H7uPw5wBp1L1LFrw3AbIpLXN8VuXkS_ThTLTZforQ6X10vYknTbCeetU7PZWnp_L01Kuee9XHLH49bzk0PbQX6Vxkxt_OuEnW-C6aYF260GQlpWIs0z6eaY_Ow-k_DOj19WciphDleYDL33G8DDDxtxaSSq5_3t5oIr_T280vru_oP_jPpgk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79384201</pqid></control><display><type>article</type><title>Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline</title><source>Alma/SFX Local Collection</source><creator>GOODFIELD, M.J.D. ; ROWELL, N.R.</creator><creatorcontrib>GOODFIELD, M.J.D. ; ROWELL, N.R.</creatorcontrib><description>Summary
Vascular problems are very common in systemic sclerosis with 95% of patients suffering with Raynaud's phenomenon at some stage in their illness.1 Acute ischaemic lesions are much less common, but when they occur are a serious complication, and are often difficult to treat. Many drugs have been used in this situation, including both oral and intravenous vaso‐dilators2,3 and low molecular weight dextran,4 each with varying degrees of success. The phosphodiesterase inhibitor, pentoxifylline, is reported to be useful in peripheral vascular disease,5 and in Raynaud's phenomenon,6 and the intravenous form is indicated for acute peripheral ischaemia, though its use in the context of connective tissue disease has not so far been reported. We now report the use of intravenous pentoxifylline in two patients with acute peripheral gangrene due to systemic sclerosis.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/j.1365-2230.1989.tb00917.x</identifier><identifier>PMID: 2598492</identifier><identifier>CODEN: CEDEDE</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Female ; Fingers - pathology ; Gangrene - drug therapy ; Gangrene - etiology ; Humans ; Infusions, Intravenous ; Male ; Medical sciences ; Pentoxifylline - administration & dosage ; Pentoxifylline - therapeutic use ; Pharmacology. Drug treatments ; Scleroderma, Systemic - complications ; Scleroderma, Systemic - pathology ; Skin, nail, hair, dermoskeleton ; Theobromine - analogs & derivatives</subject><ispartof>Clinical and experimental dermatology, 1989-03, Vol.14 (2), p.161-162</ispartof><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633</citedby><cites>FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7277944$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2598492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GOODFIELD, M.J.D.</creatorcontrib><creatorcontrib>ROWELL, N.R.</creatorcontrib><title>Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary
Vascular problems are very common in systemic sclerosis with 95% of patients suffering with Raynaud's phenomenon at some stage in their illness.1 Acute ischaemic lesions are much less common, but when they occur are a serious complication, and are often difficult to treat. Many drugs have been used in this situation, including both oral and intravenous vaso‐dilators2,3 and low molecular weight dextran,4 each with varying degrees of success. The phosphodiesterase inhibitor, pentoxifylline, is reported to be useful in peripheral vascular disease,5 and in Raynaud's phenomenon,6 and the intravenous form is indicated for acute peripheral ischaemia, though its use in the context of connective tissue disease has not so far been reported. We now report the use of intravenous pentoxifylline in two patients with acute peripheral gangrene due to systemic sclerosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fingers - pathology</subject><subject>Gangrene - drug therapy</subject><subject>Gangrene - etiology</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pentoxifylline - administration & dosage</subject><subject>Pentoxifylline - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Scleroderma, Systemic - complications</subject><subject>Scleroderma, Systemic - pathology</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Theobromine - analogs & derivatives</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><recordid>eNqVUU2P0zAUtBBoKYWfgBQhxC3Fjr9iDkioLAuoWi6VQHuxHOdl18Vxip2y7b_HUaPe8cWSZ-a9mTFCbwhekXze71aECl5WFc0PqlarscFYEbk6PkGLC_QULTDFshSK1s_Ri5R2GBNKJL9CVxVXNVPVAt1tI5ixhzAWQ1fsIbr9A0Tji3sT7iMEKNoDFONQpFMaoXe2SNZDHJJLxaMbHwoXxmj-QhgOKcvDOBxdd_LeBXiJnnXGJ3g130u0_XK9XX8tNz9uvq0_bUrLqCAlt1ZAzVpssynScgqsIQ03pGst7qgRteWmtUZCTQhmIBvWWSwFBoWVoHSJ3p3H7uPw5wBp1L1LFrw3AbIpLXN8VuXkS_ThTLTZforQ6X10vYknTbCeetU7PZWnp_L01Kuee9XHLH49bzk0PbQX6Vxkxt_OuEnW-C6aYF260GQlpWIs0z6eaY_Ow-k_DOj19WciphDleYDL33G8DDDxtxaSSq5_3t5oIr_T280vru_oP_jPpgk</recordid><startdate>198903</startdate><enddate>198903</enddate><creator>GOODFIELD, M.J.D.</creator><creator>ROWELL, N.R.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198903</creationdate><title>Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline</title><author>GOODFIELD, M.J.D. ; ROWELL, N.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fingers - pathology</topic><topic>Gangrene - drug therapy</topic><topic>Gangrene - etiology</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pentoxifylline - administration & dosage</topic><topic>Pentoxifylline - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Scleroderma, Systemic - complications</topic><topic>Scleroderma, Systemic - pathology</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Theobromine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GOODFIELD, M.J.D.</creatorcontrib><creatorcontrib>ROWELL, N.R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GOODFIELD, M.J.D.</au><au>ROWELL, N.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>1989-03</date><risdate>1989</risdate><volume>14</volume><issue>2</issue><spage>161</spage><epage>162</epage><pages>161-162</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><coden>CEDEDE</coden><abstract>Summary
Vascular problems are very common in systemic sclerosis with 95% of patients suffering with Raynaud's phenomenon at some stage in their illness.1 Acute ischaemic lesions are much less common, but when they occur are a serious complication, and are often difficult to treat. Many drugs have been used in this situation, including both oral and intravenous vaso‐dilators2,3 and low molecular weight dextran,4 each with varying degrees of success. The phosphodiesterase inhibitor, pentoxifylline, is reported to be useful in peripheral vascular disease,5 and in Raynaud's phenomenon,6 and the intravenous form is indicated for acute peripheral ischaemia, though its use in the context of connective tissue disease has not so far been reported. We now report the use of intravenous pentoxifylline in two patients with acute peripheral gangrene due to systemic sclerosis.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2598492</pmid><doi>10.1111/j.1365-2230.1989.tb00917.x</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 1989-03, Vol.14 (2), p.161-162 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79384201 |
| source | Alma/SFX Local Collection |
| subjects | Adult Aged Biological and medical sciences Female Fingers - pathology Gangrene - drug therapy Gangrene - etiology Humans Infusions, Intravenous Male Medical sciences Pentoxifylline - administration & dosage Pentoxifylline - therapeutic use Pharmacology. Drug treatments Scleroderma, Systemic - complications Scleroderma, Systemic - pathology Skin, nail, hair, dermoskeleton Theobromine - analogs & derivatives |
| title | Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20peripheral%20gangrene%20due%20to%20systemic%20sclerosis%20with%20intravenous%20pentoxifylline&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=GOODFIELD,%20M.J.D.&rft.date=1989-03&rft.volume=14&rft.issue=2&rft.spage=161&rft.epage=162&rft.pages=161-162&rft.issn=0307-6938&rft.eissn=1365-2230&rft.coden=CEDEDE&rft_id=info:doi/10.1111/j.1365-2230.1989.tb00917.x&rft_dat=%3Cproquest_cross%3E79384201%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4361-5cc6e84d0c2591d53e4b1b5a1fdc0f3a68c5adca7e81104e7b4fc0760e909633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79384201&rft_id=info:pmid/2598492&rfr_iscdi=true |